F-18 Altanserin PET Study of Patients Receiving Clozapine (APC)

This is an interventional basic science trial for Schizophrenia focused on measuring clozapine, PET, schizophrenia, schizoaffective disorder Read More

Inclusion Criteria:

• Overtly healthy males as determined by medical history and physical examination
• Age from 19 to 45 years
• Weight ≥ 45 kg and within ± 20% of IBW
• Clinical laboratory test results within normal reference range for the National Cancer Center, Hospital or results with minor deviations which are judged to be not clinically significant by the investigator
• Normal blood pressure and heart rate (supine and standing) as determined by the investigator
• Are reliable and willing to make themselves available for the duration of the study, and who will abide by the study restrictions
• Have given written informed consent

Exclusion Criteria:

• Evidence of significant active hematologic disease
• History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication
• An episode of febrile disease or infectious disease within the past 2 weeks
• Evidence of significant active neuropsychiatric disease
• Regular use of drugs or abuse
• History of drug hypersensitivity or clinically significant allergic reactions of any origin
• Participation in a study involving administration of an investigational compound within the past 30 days
• Use of any current medication
• Smoking history for recent 3 months